Healthcare provider profile · identity verified

Alan G Flores

Allopathic & Osteopathic Physicians|Family Medicine · LA VERNE, CA · NPI 1124087671

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Alan G Flores received $37.12 in general payments during 2025 across 1 reported records.

Alexion Pharmaceuticals, Inc. accounted for 100.0% of that reported general-payment amount.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$37.12

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Alexion Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $37.12100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$37.121

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Payment records were found, but the reported records did not identify a specific associated product for this analysis.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium754294
LisinoprilLisinopril326133
Amlodipine BesylateAmlodipine Besylate322135
Losartan PotassiumLosartan Potassium293119
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen24951
Metformin HclMetformin Hcl21180
Levothyroxine SodiumLevothyroxine Sodium20283
AtenololAtenolol18971
GlipizideGlipizide18569
Pantoprazole SodiumPantoprazole Sodium17255
SimvastatinSimvastatin17067
HydrochlorothiazideHydrochlorothiazide16565
Terazosin HclTerazosin Hcl15461
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide15263
OmeprazoleOmeprazole15258
Metformin Hcl ErMetformin Hcl14958
MeloxicamMeloxicam14457
Potassium ChloridePotassium Chloride14156
Trazodone HclTrazodone Hcl13548
Metoprolol TartrateMetoprolol Tartrate12753
Tamsulosin HclTamsulosin Hcl12051
Rosuvastatin CalciumRosuvastatin Calcium11857
Alendronate SodiumAlendronate Sodium11342
GabapentinGabapentin10443
Albuterol Sulfate HfaAlbuterol Sulfate9950
IbuprofenIbuprofen9539
PradaxaDabigatran Etexilate Mesylate9339
AllopurinolAllopurinol7231
Duloxetine HclDuloxetine Hcl7024
Sertraline HclSertraline Hcl7031
Fluoxetine HclFluoxetine Hcl6827
Hydralazine HclHydralazine Hcl6631
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide6221
LactuloseLactulose6028
Fluticasone PropionateFluticasone Propionate5720
CarvedilolCarvedilol5524
ClopidogrelClopidogrel Bisulfate5521
Montelukast SodiumMontelukast Sodium5521
Tramadol HclTramadol Hcl5024
Humulin NInsulin Nph Human Isophane4819
Azelastine HclAzelastine Hcl4621
Humulin N KwikpenInsulin Nph Human Isophane4612
Donepezil HclDonepezil Hcl4513
Triamcinolone AcetonideTriamcinolone Acetonide4525
Wixela InhubFluticasone Propion/Salmeterol4523
Nano 2nd Gen Pen NeedlePen Needle, Diabetic4419
FurosemideFurosemide4323
LovastatinLovastatin4316
NaproxenNaproxen4218
SpironolactoneSpironolactone4215
EzetimibeEzetimibe3914
Bisoprolol FumarateBisoprolol Fumarate3516
FinasterideFinasteride3516
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf3030
AlvescoCiclesonide2812
EliquisApixaban28suppressed
Clonidine HclClonidine Hcl2714
FamotidineFamotidine2615
JardianceEmpagliflozin24suppressed
Humulin RInsulin Regular, Human23suppressed
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid23suppressed
Veo Insulin SyringeSyringe And Needle,insulin,1ml23suppressed
Diltiazem 24hr Er (Cd)Diltiazem Hcl21suppressed
Veo Insulin SyringeSyringe-Needle,insulin,0.5 Ml20suppressed
ChlorthalidoneChlorthalidone19suppressed
Dicyclomine HclDicyclomine Hcl19suppressed
HydrocortisoneHydrocortisone19suppressed
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen19suppressed
ArexvyRsvpref3 Antigen/As01e/Pf1818
EstradiolEstradiol18suppressed
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm18suppressed
ColchicineColchicine17suppressed
Ondansetron OdtOndansetron1712
Oxybutynin Chloride ErOxybutynin Chloride17suppressed
AcyclovirAcyclovir16suppressed
FenofibrateFenofibrate16suppressed
Spiriva RespimatTiotropium Bromide16suppressed
Sumatriptan SuccinateSumatriptan Succinate16suppressed
ValsartanValsartan16suppressed
Cartia XtDiltiazem Hcl15suppressed
Propranolol HclPropranolol Hcl15suppressed
Buspirone HclBuspirone Hcl14suppressed
Hydromorphone HclHydromorphone Hcl14suppressed
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim1413
Isosorbide Mononitrate ErIsosorbide Mononitrate13suppressed
Pravastatin SodiumPravastatin Sodium13suppressed
XareltoRivaroxaban13suppressed
CephalexinCephalexin1212
Dabigatran EtexilateDabigatran Etexilate Mesylate1212
Enoxaparin SodiumEnoxaparin Sodium12suppressed
Escitalopram OxalateEscitalopram Oxalate12suppressed
Methenamine HippurateMethenamine Hippurate12suppressed
Metoprolol SuccinateMetoprolol Succinate12suppressed
TestosteroneTestosterone12suppressed
Venlafaxine Hcl ErVenlafaxine Hcl12suppressed
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc11suppressed
Bupropion XlBupropion Hcl11suppressed
NystatinNystatin11suppressed
Quetiapine FumarateQuetiapine Fumarate11suppressed
SucralfateSucralfate11suppressed
Warfarin SodiumWarfarin Sodium11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $37.12 · 1 records Alexion Pharmaceuticals, Inc.
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error